Arca
Skip to content
Tools
Tools

Bile duct cancer

Drug research and approvals for bile duct cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 232 studies of bile duct cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 5 open orphan designations naming it.

  • Recruiting worldwide: 232
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 232 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 1

Phase 2 12 of 28

Phase 1 or earlier 3

How its trials ended

205 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 46 whose ending is known, 24% met their primary endpoint, 11% missed it and 65% stopped early.

  • Completed, result not reported7537%
  • Ongoing5326%
  • Status unknown3115%
  • Stopped: other or unclear147%
  • Met its primary endpoint115%
  • Stopped: enrollment or feasibility84%
  • Missed its primary endpoint52%
  • Stopped: lack of efficacy31%
  • Stopped: sponsor or business decision31%
  • Stopped: safety1<1%
  • Stopped: funding1<1%

FDA orphan designations

Approved first, then open designations, newest first
Feb 6, 20253-bromopyruvateTreatment of liver and intrahepatic bile duct cancerCage Pharmaceuticals, Inc.Designated
Nov 26, 2024Monoclonal antibody targeting CD36Treatment of liver and intrahepatic bile duct cancerPilatus Biosciences Inc.Designated
Nov 30, 2021An ADC drug against CLDN18.2, containing a recombinant…Treatment of Cholangiocarcinoma (intrahepatic bile duct cancer)LaNova Medicines LimitedDesignated
Apr 16, 2013Opioid growth factorTreatment of liver and intrahepatic bile duct cancerPrimocure Pharma, Inc.Designated
Mar 5, 20133-bromopyruvateTreatment of liver and intrahepatic bile duct cancerKoDiscovery, LLCDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.